Monte Rosa Correlations
GLUE Stock | USD 5.66 0.10 1.74% |
The current 90-days correlation between Monte Rosa Therapeutics and DiaMedica Therapeutics is 0.02 (i.e., Significant diversification). The correlation of Monte Rosa is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Monte Rosa Correlation With Market
Significant diversification
The correlation between Monte Rosa Therapeutics and DJI is 0.02 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Monte Rosa Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Monte |
Moving together with Monte Stock
Moving against Monte Stock
0.51 | VIRX | Viracta Therapeutics | PairCorr |
0.31 | DRMA | Dermata Therapeutics | PairCorr |
0.42 | VXRT | Vaxart Inc | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Monte Stock performing well and Monte Rosa Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Monte Rosa's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
A | 1.21 | 0.03 | 0.01 | 0.09 | 1.45 | 2.72 | 8.06 | |||
EQ | 4.62 | (0.12) | 0.00 | 0.12 | 0.00 | 13.33 | 64.12 | |||
ME | 4.10 | (0.57) | 0.00 | (0.92) | 0.00 | 9.23 | 29.72 | |||
DMAC | 3.40 | 0.50 | 0.12 | 1.06 | 3.79 | 8.64 | 47.69 | |||
VALN | 2.59 | (0.33) | 0.00 | (2.30) | 0.00 | 4.80 | 25.53 | |||
VANI | 2.00 | 0.11 | 0.03 | (4.45) | 2.53 | 5.11 | 20.23 | |||
DNTH | 3.15 | (0.30) | 0.00 | (0.48) | 0.00 | 7.64 | 23.93 | |||
DOMH | 3.39 | (0.48) | 0.00 | (0.81) | 0.00 | 8.89 | 32.92 | |||
VCEL | 1.79 | 0.53 | 0.29 | 1.63 | 1.41 | 5.15 | 12.86 |
Monte Rosa Corporate Management
Filip MD | Chief Officer | Profile | |
Jennifer Champoux | VP Operations | Profile | |
Sharon Townson | Chief Officer | Profile | |
Edmund Dunn | Vice Controller | Profile | |
John Castle | Chief Scientist | Profile | |
Magnus DPHIL | Senior Development | Profile |